A Phase 3 interventional study of Tolvaptan in Hyponatremia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 7 sites in 3 countries. Open to participants aged 4 Weeks to 17 Years. Per ClinicalTrials.gov, last updated 2018-09-26.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.
Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 15th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 14th registered.
164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.
Browse Hyponatremia studies →None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 4 Weeks to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 10 · Phase 4 7
First in 2003; this study’s year is marked. 3 started in 2015.
This study's enrollment of 9 is below the median of 60 across 97 interventional studies indexed under Hyponatremia.
Median enrollment 55 across the 20 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Hyponatremia by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 17 studies in Hyponatremia by Otsuka Holdings Co., Ltd., this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2015, is one of 8 in phase 3, and was the 10th registered.
Otsuka Holdings Co., Ltd.’s Hyponatremia studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing tolvaptan in Hyponatremia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Hyponatremia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial was to demonstrate that tolvaptan effectively and safely increases and maintains serum sodium concentrations in children and adolescent participants with euvolemic or hypervolemic hyponatremia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment. At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 millimoles/liter \[mmol/L\]) were randomized to either the Early or Late Withdrawal Group. Non-responders could continue treatment with tolvaptan for an additional 2 days. Discontinued tolvaptan treatment immediately after randomization. All participants were observed up to 14 days post randomization.
Drug: Tolvaptan
All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment. At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 mmol/L) were randomized to either the Early or Late Withdrawal Group in Treatment Phase B. Non-responders could continue treatment with tolvaptan for an additional 2 days. Continued treatment for 2 additional days. All participants were observed up to 14 days post randomization.
Drug: Tolvaptan
Also known as: SAMSCA®
Change In Serum Sodium Concentration For Responders
Change in serum sodium concentration (mEq/L) for responders from Day 2 (or Day 2a) at the end of Treatment Phase A (where all participants received tolvaptan) to the end of Treatment Phase B for the Early compared to Late Withdrawal groups is reported. Once a participant was randomized to Treatment Phase B, any additional therapies for the purpose of raising serum sodium, including fluid restriction, were considered rescue therapy. Upon receipt of rescue therapy, a participant's endpoint data was collected and then censored from the efficacy analysis thereafter, unless specified.
Time frame: Day 2/2a, Day 4
Change In Serum Sodium Concentration During Treatment Phase A
Change in serum sodium concentration (mEq/L) from baseline to the end of Day 2 (or 2a) during Treatment Phase A for all participants (responders and non-responders) is reported.
Time frame: Baseline, Day 2/2a
Fluid Balance (Intake Minus Output) During Treatment Phase A
Every 6 hours and for the 24-hour daily interval on Days 1 and 2 during Treatment Phase A, fluid balance (milliliters \[mL\]) was determined by fluid intake (oral and intravenous) minus urine output. Improved fluid balance would be indicated through the induction of increased urine volume. Fluid balance was monitored per institutional guidelines.
Time frame: Every 6 hours on Days 1 and 2
| Milestone | Treatment Phase A | Treatment Phase B: Responder - Late Withdrawal | Treatment Phase B: Responder - Early Withdrawal | Treatment Phase B: Non-responder - Study Drug | Treatment Phase B: Non-responder - Standard of Care |
|---|---|---|---|---|---|
| Started | 9 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 9 | 0 | 0 | 0 | 0 |
| Completed | 7 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Phase A | Treatment Phase B: Responder - Late Withdrawal | Treatment Phase B: Responder - Early Withdrawal | Treatment Phase B: Non-responder - Study Drug | Treatment Phase B: Non-responder - Standard of Care |
|---|---|---|---|---|---|
| Started | 0 | 2 | 3 | 1 | 1 |
| Received at least 1 dose of study drug | 0 | 2 | 3 | 1 | 1 |
| Completed | 0 | 2 | 3 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Change in serum sodium concentration (mEq/L) for responders from Day 2 (or Day 2a) at the end of Treatment Phase A (where all participants received tolvaptan) to the end of Treatment Phase B for the Early compared to Late Withdrawal groups is reported. Once a participant was randomized to Treatment Phase B, any additional therapies for the purpose of raising serum sodium, including fluid restriction, were considered rescue therapy. Upon receipt of rescue therapy, a participant's endpoint data was collected and then censored from the efficacy analysis thereafter, unless specified.
| mEq/L | Responder - Late Withdrawal | Responder - Early Withdrawal |
|---|---|---|
| Change In Serum Sodium Concentration For Responders | -4.0 ± 4.2 | -1.0 ± 1.0 |
Change in serum sodium concentration (mEq/L) from baseline to the end of Day 2 (or 2a) during Treatment Phase A for all participants (responders and non-responders) is reported.
| mEq/L | Phase A: All Participants |
|---|---|
| Day 1: 24 hours Post Dose | 1 ± 3 |
| Day 2: 24 hours Post Dose | 3.4 ± 4.8 |
| Day 2a: 24 hours Post Dose | 2.3 ± 2.1 |
Every 6 hours and for the 24-hour daily interval on Days 1 and 2 during Treatment Phase A, fluid balance (milliliters \[mL\]) was determined by fluid intake (oral and intravenous) minus urine output. Improved fluid balance would be indicated through the induction of increased urine volume. Fluid balance was monitored per institutional guidelines.
| mL | Phase A: All Participants |
|---|---|
| Day 1: 0-6 hours | -1 ± 505 |
| Day 1: 6-12 hours | -261 ± 533 |
| Day 1: 12-18 hours | -36 ± 253 |
| Day 1: 18-24 hours | 31 ± 344 |
| Day 1: 0-24 hours | -268 ± 849 |
| Day 2: 0-6 hours | -101 ± 376 |
| Day 2: 6-12 hours | 6 ± 513 |
| Day 2: 12-18 hours | -45 ± 400 |
| Day 2: 18-24 hours | -21 ± 191 |
| Day 2: 0-24 hours | -160 ± 733 |
Collected over From screening through early termination or follow-up phase (14 days postrandomization).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Phase A | 0/9 (0%) | 2/9 (22.2%) | 3/9 (33.3%) |
| Treatment Phase B: Responder - Late Withdrawal | 0/2 (0%) | 1/2 (50%) | 1/2 (50%) |
| Treatment Phase B: Responder - Early Withdrawal | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Treatment Phase B: Non-responder - Study Drug | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Treatment Phase B: Non-responder - Standard of Care | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Treatment Phase A | Treatment Phase B: Responder - Late Withdrawal | Treatment Phase B: Responder - Early Withdrawal | Treatment Phase B: Non-responder - Study Drug | Treatment Phase B: Non-responder - Standard of Care |
|---|---|---|---|---|---|
| Catheter site extravasationGeneral disorders | 0/9 | 0/2 | 0/3 | 1/1 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 0/9 | 1/2 | 0/3 | 0/1 | 0/1 |
| Medical device site haemorrhageGeneral disorders | 1/9 | 0/2 | 0/3 | 0/1 | 0/1 |
| Faecal volume increasedGastrointestinal disorders | 1/9 | 0/2 | 0/3 | 0/1 | 0/1 |
| Event | Treatment Phase A | Treatment Phase B: Responder - Late Withdrawal | Treatment Phase B: Responder - Early Withdrawal | Treatment Phase B: Non-responder - Study Drug | Treatment Phase B: Non-responder - Standard of Care |
|---|---|---|---|---|---|
| Blood sodium decreasedInvestigations | 0/9 | 0/2 | 0/3 | 0/1 | 1/1 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/9 | 0/2 | 0/3 | 1/1 | 0/1 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/9 | 0/2 | 0/3 | 1/1 | 0/1 |
| Nasal inflammationRespiratory, thoracic and mediastinal disorders | 0/9 | 0/2 | 0/3 | 0/1 | 1/1 |
| Fluid overloadMetabolism and nutrition disorders | 0/9 | 0/2 | 0/3 | 1/1 | 0/1 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/9 | 0/2 | 0/3 | 1/1 | 0/1 |
| HyponatraemiaMetabolism and nutrition disorders | 0/9 | 0/2 | 0/3 | 1/1 | 0/1 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/9 | 1/2 | 0/3 | 0/1 | 0/1 |
| Upper respiratory tract infectionInfections and infestations | 0/9 | 1/2 | 0/3 | 0/1 | 0/1 |
| BradycardiaCardiac disorders | 0/9 | 0/2 | 1/3 | 0/1 | 0/1 |
Intent-to-treat (ITT) population - Provided following 3 core datasets used for all efficacy analyses: Treatment Phase A; Treatment Phase B responders; Treatment Phase B non-responders.
| Age, Continuous(years) | Treatment Phase A |
|---|---|
| Mean | 6.1 ± 5.1 |
| Sex: Female, Male(Participants) | Treatment Phase A |
|---|---|
| Female | 3 |
| Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Phase A |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 5 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(Participants) | Treatment Phase A |
|---|---|
| White | 6 |
| Black or African American | 1 |
| American Indian or Alaskan Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Other | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Jul 2017, 22 months.
Results were first posted in Aug 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Development & Commercialization, Inc. →